alexa Saxagliptin Responder Analysis: A Pooled Analysis of 5 Clinical Trials | OMICS International | Abstract
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Saxagliptin Responder Analysis: A Pooled Analysis of 5 Clinical Trials

Mikaela Sjostrand1, Gil Leibowitz2, Nayyar Iqbal3, William Cook3, Cheryl Wei3 and Boaz Hirshberg4*

1AstraZeneca, Mölndal, Sweden

2Hadassah Medical Center, Jerusalem, Israel

3AstraZeneca, Gaithersburg, MD, USA

4MedImmune, LLC, Gaithersburg, MD, USA

Corresponding Author:
Boaz Hirshberg
Clinical Therapeutic Area Head
Cardiovascular/Metabolic Disease (CVMD) MedImmune
LLC One MedImmune Way, Building 200 Gaithersburg, MD 20878, USA
Tel: 301-398-0645
Fax: (301) 398-9865
E-mail: [email protected]

Received Date: October 09, 2015; Accepted March 10, 2016; Published Date: March 17, 2016

Citation: Sjostrand M, Leibowitz G, Iqbal N, Cook W, Wei C, et al. (2016) Saxagliptin Responder Analysis: A Pooled Analysis of 5 Clinical Trials. J Diabetes Metab 7:657. doi:10.4172/2155-6156.1000657

Copyright: © 2016 Sjostrand M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Objective: To assess the treatment response of patients with T2DM to saxagliptin at 24 weeks based on their initial response to saxagliptin at 12 weeks. Methods: Data were pooled from five 24-week, randomized, placebo-controlled trials of saxagliptin. Patients (N=1994) were categorized by change in glycated hemoglobin (HbA1c) after 12 weeks of saxagliptin treatment as responders (HbA1c decrease ≥ 0.5%; 61% of saxagliptin-treated patients), intermediate responders (HbA1c decrease ≥ 0.2% and <0.5%; 14% of patients), and nonresponders (HbA1c decrease <0.2%; 25% of patients). Results: The adjusted mean change [95% CI] from baseline to week 24 in HbA1c with saxagliptin was greatest in responders (–1.05% [–1.11%, – 0.99%]) followed by intermediate responders (–0.32% [–0.43%, –0.22%]) and nonresponders (0.27% [0.18%, 0.36%]). The proportion of patients achieving HbA1c<7% after 24 weeks was greater in responders (48%) and intermediate responders (41%) versus nonresponders (22%, P<0.0001 for each). The adjusted mean increase from baseline to week 24 in HOMA-2%β was greatest in the responder group (16.9% [13.5%, 20.2%]) compared with the other groups (intermediate responders, 11.7% [5.9%, 17.5%]; nonresponders, 0.4% [–4.8%, 5.6%]). Baseline characteristics that were associated with glycemic response to saxagliptin included higher baseline HbA1c (P<0.0001), higher HOMA-2%β (P<0.0001), lower fasting insulin (P=0.0006), shorter T2DM duration (P=0.033), and male sex (P=0.031). Conclusion: Responders, who comprised 61% of saxagliptin-treated patients analyzed, derived significant benefit from saxagliptin, with a ~1% decline in HbA1c and increased β-cell function at 24 weeks compared with nonresponders.


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]om

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7